20 June 2012 – Vascular disease specialist Veryan has announced the appointment of Nick Yeo as Chief Operating Officer.
Nick has over 20 years’ international experience in the healthcare industry. He began his career in pharmaceuticals, becoming CEO of Sterling Winthrop Prescription Medicines, before moving on to senior marketing and business leadership roles at Gensia Europe and Scotia QuantaNova. Before joining Veryan he held senior management positions in product and clinical development at oncology drug-device specialist Light Sciences, where he led the formation of a cardiovascular technology startup.
“We are delighted that Nick has joined us at such an exciting stage of the company’s development”, commented Veryan Chief Executive Chas Taylor. “His specific expertise will prove particularly valuable as we gear up towards a regulatory submission in Europe for our BioMimics 3D Stent”.
About Veryan
Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan’s BioMimics 3D™ stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to improve clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.
Pre-clinical studies have shown that BioMimics 3D stent technology may significantly reduce restenosis (the narrowing of stented arterial segments) and confer significant mechanical benefits: the BioMimics 3D stent is more flexible, kink and fracture resistant than conventional counterparts.
Veryan has completed enrolment in a pivotal randomised study, MIMICS, and intends to submit a CE Mark application for the BioMimics 3D stent later this year.
For further information, please contact:
Richard Kenyon
richard@rkpr.co.uk
+44 7831 569940
